All data are based on the daily closing price as of February 7, 2025
r

RaQualia Pharma

4579.TSE
2.63 USD
0.00
0.00%

Overview

Last close
2.63 usd
Market cap
56.88M usd
52 week high
6.42 usd
52 week low
2.32 usd
Target price
7.91 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
3.7571
Price/Book Value
1.5401
Enterprise Value
60.66M usd
EV/Revenue
4.0061
EV/EBITDA
10.6691

Key financials

Revenue TTM
15.14M usd
Gross Profit TTM
19.23M usd
EBITDA TTM
-1.36M usd
Earnings per Share
-0.21 usd
Dividend
N/A usd
Total assets
62.97M usd
Net debt
3.37M usd

About

RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 3 clinical trial in the United States; and grapiprant for cancer, which is in phase I clinical trial in China and the United States, as well as grapiprant for pain management The company also provides veterinary products, such as grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the indication of chronic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial; Cyclooxygenase-2 inhibitor, which is in phase I clinical trials for the indication of pain; CB2 agonist for pain; selective sodium channel blocker for pain and itch; P2X7 receptor antagonist, which is in Phase 2 clinical trials for the target indication of chronic pain. It has a collaborative agreement with Socium Corporation and Epigeneron, Inc. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.
  • Symbol
    4579.TSE
  • Exchange
    TSE
  • Isin
    JP3967150008
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
  • Headquarter
    Nagoya
  • Web site
    https://www.raqualia.co.jp
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top